Rapidly maturing field of proteomics: A gateway to studying diseases

Proteomics

Volumn 14, Issue 9, 2014, Pages 991-993

  Schutzer, Steven E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Biomedicine; Cerebrospinal fluid; Mass spectrometry; Neurologic disease

Indexed keywords

BIOLOGICAL MARKER; PROTEOME; PROTEIN CEREBROSPINAL FLUID LEVEL;

AMINO ACID SEQUENCE; BIODIVERSITY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CROSS REACTION; DISEASES; HUMAN; MASS SPECTROMETRY; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; WESTERN BLOTTING; ANALYSIS; ANIMAL; MALE; PROCEDURES; PROTEIN CEREBROSPINAL FLUID LEVEL;

ANIMALS; CEREBROSPINAL FLUID PROTEINS; MALE; MASS SPECTROMETRY; PROTEOME; PROTEOMICS;

EID: 84898648656     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400091     Document Type: Note

References (13)

1. Smith, J. S., Angel, T. E., Chavkin, C., Orton, D. J. et al., Characterization of individual mouse cerebrospinal fluid proteomes. Proteomics 2014, 14, 1102-1106.
2. Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C. et al., Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol. Cell. Proteomics 2014, 13, 907-917.
3. Smith, R. D., Mass spectrometry in biomarker applications: from untargeted discovery to targeted verification, and implications for platform convergence and clinical application. Clin. Chem. 2012, 58, 528-530.
4. Ransohoff, R. M., Engelhardt, B., The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 2012, 12, 623-635.
5. Shi, T., Fillmore, T. L., Sun, X., Zhao, R. et al., Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 15395-15400.
6. Aebersold, R., Burlingame, A. L., Bradshaw, R. A., Western Blots vs. SRM Assays: time to turn the tables? Mol. Cell. Proteomics. 2013, 12, 2381-2382.
7. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnology. 2006, 24, 971-983.
8. Ning, M. M., Lopez, M., Sarracino, D., Cao, J. et al., Pharmaco-proteomics opportunities for individualizing neurovascular treatment. Neurol. Res. 2013, 35, 448-456.
9. Liu, T., Hossain, M., Schepmoes, A. A., Fillmore, T. L. et al., Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J. Proteomics 2012, 75, 4747-4757.
10. Qian, W. J., Petritis, B. O., Kaushal, A., Finnerty, C. C. et al., Plasma proteome response to severe burn injury revealed by 18O-labeled "universal" reference-based quantitative proteomics. J. Proteome Res. 2010, 9, 4779-4789.
11. Anderson, N. L., Anderson, N. G., Pearson, T. W., Borchers, C. H. et al., A human proteome detection and quantitation project. Mol. Cell. Proteomics 2009, 8, 883-886.
12. Aebersold, R., Bader, G. D., Edwards, A. M., Van, E. J. et al., Highlights of B/D-HPP and HPP resource pillar workshops at Yokohama 12 Annual HUPO World Congress of Proteomics. Proteomics 2014, 14, 975-988.
13. Schutzer, S. E., Keim, P., Czerwinski, K., Budowle, B., Use of forensic methods under exigent circumstances without full validation. Sci. Transl. Med. 2009, 1, 8cm7.